BioSolutions Clinical Research Center

CURRICULUM VITAE

SIGNATURE:		**DATE:**	10/27/17
NAME: **TITLE:**	Peter B. Hanson, MD Principal Investigator	**DATE UPDATED:**	October 2017

RESEARCH SITE ADDRESS & PHONE:

Main Office: BioSolutions Clinical Research Center 5565 Grossmont Center Dr. Bldg 3 Suite 253 La Mesa CA 91942	 Office: (619) 637-0770 Fax: (619) 713-0156 Email: drhanson@biosolutionsresearch.com

EDUCATION/TRAINING:

INSTITUTION AND LOCATION	DEGREE *(if applicable)*	YEAR(s)	FIELD OF STUDY
Occidental College Los Angeles, California	B.A.	1982	Biology
University of California, Irvine College of Medicine, Irvine, California	M.D.	1986	Medicine
University of California, Davis Medical Center Sacramento, California	Internship	1987	General Surgery
University of California, Davis Medical Center Sacramento, California	Residency	1991	Orthopedics
Scripps Clinic and Research Foundation	Fellowship	1992	Lower Extremity Reconstruction

BOARD CERTIFIED:

BOARD CERTIFIED/ELIGIBLE	YEAR(s)	SPECIALTY
Board Certified	1994	Orthopedic Surgery

POSITIONS AND EMPLOYMENT:

2014-Present	Principal Investigator, BioSolutions Clinical Research Center, La Mesa, CA
1997-Present	Medical Director Orthopaedics, Sharp Grossmont Hospital, La Mesa, CA
1992-Present	Physician, Grossmont Orthopedic Medical Group, La Mesa, CA
1992-Present	Orthopedic Surgeon, Sharp Grossmont Hospital, La Mesa, CA

2010-Present	Orthopedic Surgeon, Sharp Coronado Hospital, Coronado, CA
1994-Present	Orthopedic Supervisory Committee, Sharp Grossmont Hospital, La Mesa, CA
1995-1996	Chairman Orthopedic Department, Sharp Grossmont Hospital, La Mesa, CA

PUBLICATIONS:

1) Hanson, P.B., Montesano, P.X., Sharkey, N.A., and W. Rauschning: Anatomic and biomechanical assessment of transarticular screw fixation for atlanto-axial instability.Published: ***Spine***, 1991.

2) Hanson, P.B., Milne, J., and M.W. Chapman: Open pelvis fractures: A critical analysis. Published: ***Journal of Bone and Joint Surgery***. 73-B, p. 325, 1991. Honored: Best Paper, Pelvis and Acetabular Fractures, Orthopaedic Trauma Association, 1989.

3) Montesano, P.X., Juach, E.C., Anderson, P.A., Benson, D.R., and P.B. Hanson: Biomechanics of Cervical Spine Internal Fixation. Published: ***Spine*** 16: S10-S16, 1991.

4) Sharkey, N.A., Marder, R.A., and P.B. Hanson: The Entire Rotator Cuff Contributes to Elevation of the Arm.
Published: ***Journal of Orthopaedic Research***. Vol. 12, No. 5, 1994.

5) Hanson, P.B. and R.H. Walker: Total hip arthroplasty cemented femoral stem distal centralizer: effect on stem alignment and cement mantle thickness.
Published: ***The Journal of Arthroplasty***. Vol. 10, No. 5, October, 1995.

6) Grady-Benson, J., Oishi, C.S., Hanson, P.B., Colwell, C.W., Otis, S.M., and R.H. Walker: Postoperative Surveillance for Deep Venous Thrombosis with Duplex Ultrasonography after Total Knee Arthroplasty.
Published: ***The Journal of Bone and Joint Surgery***. 76-A, No. 11, November, 1994.

7) Oishi, C.S., Williams, V., Hanson, P.B., Schneider, J., Colwell, C.W., and R.H. Walker: Postoperative Bladder Management After Primary Total Hip Arthroplasty. Published: ***Journal of Arthroplasty***. Vol. 10, No. 6, December 1995.

8) Hull, R.D., Pineo, G.F., et el: Low-Molecular-Weight Heparin Prophylaxis Using Dalteparin in Close Proximity to Surgery vs. Warfarin in Hip Arthroplasty Patients. A Double-blind, Randomized Comparison.
Published: Archives of Internal Medicine. Vol. 160, July, 2000.

9) Gaylis, et al: Preprinted Standardized Orders Promote Venous Thromboembolism Prophylaxis Compared With Traditional Handwritten Orders: An Endorsement of Standardized Evidence-Based Practice. Published: American Journal of Medical Quality. Vol 25: 449-456, Nov/Dec 2010

CLINICAL RESEARCH EXPERIENCE:

Principal Investigator: Diatide. Phase III clinical Trial for Technitium Tc 99m P280. Radionucleotide tool for investigation of deep venous thrombosis.

Principal Investigator: Trega Biosciences. Phase II Multicenter Study for HP228. An anti-cytokin for use in pain control Total Hip Replacements.

Principal Investigator: Heamacure Inc. Hemaseal Multicenter Study for Total Knee Replacements. Fibrin sealant.

Principal Investigator: Astra-Zeneca. Phase III Study on oral anti thrombin for DVT prophylaxis in Total Knee Replacement.

Principal Investigator: Emisphere. Phase II and Phase III studies. Oral heparin for DVT prophylaxis in Total Hip Replacements.

Principal Investigator: Pharmacia/Upjohn. Fragmin Total Knee DVT study.

Principal Investigator: Pfizer oral Factor X-A inhibitor in TKA patients.

Principal Investigator: Bristol-Myers-Squibb. Use of Oral Xa inhibitor in Total Knee Replacements.

Sub Investigator: Cell Surgical Network. Autologous adipose derived stromal vascular fraction deployment.

Sub Investigator: Organon/Sanofi. Injectable Xa inhibitor (Arixtra) in DVT prophylaxis for Total Hip and Total Knee Replacements.

Sub Investigator: Implex. Ceramic-on-ceramic Total Hip Replacements.

Sub Investigator: Novartis. Injectable zoleclonic acid for prevention of osteoporosis.

Sub Investigator: Auxillium Pharmaceuticals, Inc.: A Randomized, Double-Blind, Placebo-Controlled Study Of The Safety And Efficacy of XXXX For The Treatment Of Adhesive Capsulitis Of The Shoulder

Sub Investigator Flexion: A Double-Blind, Randomized, Parallel Group, Dose-Ranging Study to Assess the Safety and Efficacy of XXXX for the Treatment of Pain in Patients with Osteoarthritis of the Knee

Sub Investigator Samumed: A Phase 1, Placebo-Controlled, Double-Blind, Dose-Escalation Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of XXXX injected in the Target Knee Joint of Moderately to Severely Symptomatic Osteoarthritis Subjects

Sub Investigator Kowa Research Institute, Inc.: A Phase III, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of XXXX Compared With Placebo for the Treatment of Mild to Moderate Acute Pain Associated With Ankle Strain or Sprain

Sub Investigator Pfizer Pharmaceuticals: A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of the Analgesic Efficacy and Safety of the Subcutaneous Administration of XXXX in Patients with Osteoarthritis of the Knee

Sub Investigator Regeneron Pharmaceuticals: A Phase II, Randomized, Double Blind, Placebo Controlled, Parallel-Group Study of the safety and efficacy of subcutaneously administered XXXX in patients with Sciatic Pain

Sub Investigator Ortho-McNeil Janssen Scientific Affairs, LLC, A Prospective Phase IV, Multi-Center, Observational Registry of Patients Using Prescription Medications Containing Oxycodone Immediate Release for the Treatment of Pain

Sub Investigator Ferring Pharmaceuticals: A Phase II, 26 week, Double blind, Randomized, Placebo controlled trial of the efficacy and safety of single Intra-Articular injection 1.2% sodium Hyaluronate for treatment of painful Osteoarthritis of the knee, with optional 26 week open-label extension

Liventa Bioscience AmnioClear™ LCT Knee Registry.

Celution Prepared Adipose Derived Regenerative Cells in the Treatment of OsteoArthritis of the Knee: A Double-blind, Placebo Controlled, Multi-center Safety and Feasibility Study.

Centrexion a phase 2 study to evaluate the analgesic efficacy of two dose levels of CNTX-XXXX, compared to placebo at 4 weeks, when administered as a single (AI) injection to the index knee in patients with knee Osteoarthritis with pain score 5-9.

Novum a phase 3 study to evaluate the efficacy & safety of a generic Diclofenac Gel 1% in patients with knee Osteoarthritis.

Viking a Phase 2a Study ambulatory and recovery from subjects 1st hip fracture 2 to 7 weeks post injury.

Pfizer a phase 2a study a monoclonal antibody that binds to and inhibits the actions of nerve growth factor in patient with knee Osteoarthritis.

Axsome a phase 3 study to assess the Efficacy and Safety of XXXX-02 administered orally to subjects with knee osteoarthritis associated with bone marrow lesions

Lannett a phase 3 investigation of topical application of Cocaine HCL 4% solution on safety and efficacy and Cocaine HCL 10% solution on safety in local (topical) anesthesia for diagnostic procedures and surgeries on or through the accessible mucous membranes of the nasal cavities

Abbvie Phase 2a Study evaluating the safety, efficacy and Pharmacodynamic effects of XXX-XXX in patients with knee osteoarthritis

Pfizer Pharmaceuticals: A Phase III. Multi-Center, Randomized, Double blind, Controlled study of the long term analgesic efficacy of XXXX alone or in combination with non-steroidal anti-inflammatory drugs (NSAIDS) versus NSAIDS alone in patients with Osteoarthritis of the knee or hip

Samumed Phase 2 Study 24 week, multicenter, randomized double blind placebo-controlled study Evaluating the safety and efficacy of XXXXX for the treatment of moderately to severely symptomatic knee osteoarthritis

Regeneron Phase 3 Randomized double-blind, multi-dose, Placebo and Naproxen controlled study to evaluate the efficacy and safety of Fasinumab in patients with pain due to osteoarthritis of the hip or knee

Centrexion Phase 3 Randomized, Double-blind, Placebo-controlled, Single, Injection, 52-Week Study to Evaluate the Efficacy and Safety of an Intra-articular Injection of CNTX-4975-05 in Subjects with Chronic, Moderate-to-severe Osteoarthritis Knee Pain

A Randomized, Double-blind, Parallel Group, Multicenter Study to Compare the Pharmacokinetics, Pharmacodynamics, Safety, and Efficacy of SAIT101 versus MabThera® versus Rituxan® in Patients with Rheumatoid Arthritis (RA).

A Phase 3, Multicenter, Observational Long-term Study Evaluating the Safety, Tolerability, and Efficacy of Treatment of SMXXXXX or Placebo Previously Injected in the Target Knee Joint of Subjects with Moderately to Severely Symptomatic Osteoarthritis

A Phase III, Multicenter, Randomized, Double-Blind Clinical Trial to Assess the Efficacy and Safety of Ciprofloxacin 0.3% plus Fluocinolone acetonide 0.025% Otic Solution Compared to Ciprofloxacin 0.3% Otic solution and to Fluocinolone acetonide 0.025% Otic Solution in the Treatment of Acute Otitis Externa (AOE)

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of BMS-XXXXX in Subjects with Systemic Lupus Erythematosus

Phase 2A, FX0016-XX-XXX, A Randomized, open-label, study comparing the systemic exposure to Triamcinilone Acetonide following a single Intra-articular injection of Extended release FXXXX, or immediate release TAcs (Triamcinilone Acetonide Suspension) in patients with osteoarthritis of the shoulder (Glenohumeral) or hip